利索基奥仑赛作为大B细胞淋巴瘤二线治疗:3期TRANSFORM研究的主要分析
这项全球3期研究比较利索基奥仑赛(liso-cel)与标准治疗用于原发难治或早期复发(≤12个月)大B细胞淋巴瘤的二线治疗。184例适合自体干细胞移植的成人按1:1随机分配。中位随访17.5个月,liso-cel组无事件生存未达到 vs 标准治疗组2.4个月,完全缓解率74% vs 43%(P<.0001),支持liso-cel作为首选二线治疗。
要点
- liso-cel组完全缓解率74% vs 标准治疗组43%(P<.0001)。
- liso-cel组中位无进展生存未达到 vs 标准治疗组6.2个月(HR=0.400;P<.0001)。
- liso-cel组3级细胞因子释放综合征和神经系统事件分别占1%和4%,无4级或5级事件。
核心结论
- 数据表明liso-cel较标准治疗在无事件生存、完全缓解率和无进展生存方面有显著改善,支持liso-cel作为原发难治或早期复发大B细胞淋巴瘤患者的首选二线治疗。
研究设计与样本
- 全球3期研究,比较liso-cel与标准治疗作为原发难治或早期复发(≤12个月)大B细胞淋巴瘤的二线治疗。
- 适合自体干细胞移植的成人(N=184)按1:1随机分配至liso-cel(100×10^6嵌合抗原受体阳性T细胞)或标准治疗(3周期铂类免疫化疗,应答者后续接受大剂量化疗和自体干细胞移植)。
- 主要终点为无事件生存。
- 试验注册号NCT03575351。
主要发现
- 中位随访17.5个月,liso-cel组中位无事件生存未达到 vs 标准治疗组2.4个月。
- 完全缓解率liso-cel组74% vs 标准治疗组43%(P<.0001)。
- 中位无进展生存liso-cel组未达到 vs 标准治疗组6.2个月(HR=0.400;P<.0001)。
- 中位总生存liso-cel组未达到 vs 标准治疗组29.9个月(HR=0.724;P=.0987)。
- 校正标准治疗组交叉至liso-cel后,18个月总生存率liso-cel组73% vs 标准治疗组54%(HR=0.415)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This global phase 3 study compared lisocabtagene maraleucel (liso-cel) with a standard of care (SOC) as second-line therapy for primary refractory or early relapsed (≤12 months) large B-cell lymphoma (LBCL). Adults eligible for autologous stem cell transplantation (ASCT; N = 184) were randomly assigned in a 1:1 ratio to liso-cel (100 × 106 chimeric antigen receptor-positive T cells) or SOC (3 cycles of platinum-based immunochemotherapy followed by high-dose chemotherapy and ASCT in responders). The primary end point was event-free survival (EFS). In this primary analysis with a 17.5-month median follow-up, median EFS was not reached (NR) for liso-cel vs 2.4 months for SOC. Complete response (CR) rate was 74% for liso-cel vs 43% for SOC (P < .0001) and median progression-free survival (PFS) was NR for liso-cel vs 6.2 months for SOC (hazard ratio [HR] = 0.400; P < .0001). Median overall survival (OS) was NR for liso-cel vs 29.9 months for SOC (HR = 0.724; P = .0987). When adjusted for crossover from SOC to liso-cel, 18-month OS rates were 73% for liso-cel and 54% for SOC (HR = 0.415). Grade 3 cytokine release syndrome and neurological events occurred in 1% and 4% of patients in the liso-cel arm, respectively (no grade 4 or 5 events). These data show significant improvements in EFS, CR rate, and PFS for liso-cel compared with SOC and support liso-cel as a preferred second-line treatment compared with SOC in patients with primary refractory or early relapsed LBCL. This trial was registered at www.clinicaltrials.gov as #NCT03575351.
引用
- Abramson JS, Solomon SR, Arnason J, et al. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study. Blood. 2023. PMID: 36542826. doi:10.1182/blood.2022018730
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。